| Literature DB >> 24656405 |
Satish Srinivas Kitambi1, Enrique M Toledo1, Dmitry Usoskin1, Shimei Wee2, Aditya Harisankar3, Richard Svensson4, Kristmundur Sigmundsson5, Christina Kalderén5, Mia Niklasson6, Soumi Kundu6, Sergi Aranda1, Bengt Westermark6, Lene Uhrbom6, Michael Andäng2, Peter Damberg7, Sven Nelander6, Ernest Arenas1, Per Artursson4, Julian Walfridsson3, Karin Forsberg Nilsson6, Lars G J Hammarström5, Patrik Ernfors8.
Abstract
Glioblastoma multiforme (GBM) is the most aggressive form of brain cancer with marginal life expectancy. Based on the assumption that GBM cells gain functions not necessarily involved in the cancerous process, patient-derived glioblastoma cells (GCs) were screened to identify cellular processes amenable for development of targeted treatments. The quinine-derivative NSC13316 reliably and selectively compromised viability. Synthetic chemical expansion reveals delicate structure-activity relationship and analogs with increased potency, termed Vacquinols. Vacquinols stimulate death by membrane ruffling, cell rounding, massive macropinocytic vacuole accumulation, ATP depletion, and cytoplasmic membrane rupture of GCs. The MAP kinase MKK4, identified by a shRNA screen, represents a critical signaling node. Vacquinol-1 displays excellent in vivo pharmacokinetics and brain exposure, attenuates disease progression, and prolongs survival in a GBM animal model. These results identify a vulnerability to massive vacuolization that can be targeted by small molecules and point to the possible exploitation of this process in the design of anticancer therapies.Entities:
Mesh:
Substances:
Year: 2014 PMID: 24656405 DOI: 10.1016/j.cell.2014.02.021
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582